China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.
The planned solution will enable secondary and tertiary analysis and visualization of single-cell sequence data.
The company said its organic revenue growth during the quarter was 4 percent, and that acquisitions increased revenue by 3 percent.
As part of a development and global distribution agreement, the companies will develop and launch a kit directed towards mitigating a growing HAI-related concern.
Thermo Fisher will become the exclusive distributor for a technology to be developed with Boston-based Cytonome.
The assay will detect multiple classes of genomic alterations across a range of genes involved in homologous recombination repair.
The companies intend to bring companion diagnostics through US Food and Drug Administration clearance using ArcherDX's AMP chemistry and Illumina's MiSeqDx.
The companies will develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.
The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.
Both companies are working together to market both companies' technology for long-read DNA sequencing.
Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.
Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.
A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.